Roche/Genentech, OSI to pay $67M to Settle Drug Claims

Jun 08, 2016


Genentech and OSI Pharmaceuticals will be paying $67 million to resolve claims they made misleading statements about the effectiveness of lung cancer drug Tarceva, according to the U.S. Justice Department, as reported in a Reuters article.

The claims alleged that between 2006 and 2011, the companies misrepresented the drug to doctors and healthcare providers to treat patients with non-small cell lung cancer, the department said.

As a part of the settlement, the federal government will get $62.6 million and state Medicaid programs will get $4.4 million.

Read the Reuters story